344 related articles for article (PubMed ID: 26276716)
1. Reprogramming cancer cells: a novel approach for cancer therapy or a tool for disease-modeling?
Yilmazer A; de Lázaro I; Taheri H
Cancer Lett; 2015 Dec; 369(1):1-8. PubMed ID: 26276716
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic regulation leading to induced pluripotency drives cancer development in vivo.
Ohnishi K; Semi K; Yamada Y
Biochem Biophys Res Commun; 2014 Dec; 455(1-2):10-5. PubMed ID: 25019993
[TBL] [Abstract][Full Text] [Related]
3. Induced pluripotent stem cell technology for dissecting the cancer epigenome.
Semi K; Yamada Y
Cancer Sci; 2015 Oct; 106(10):1251-6. PubMed ID: 26224327
[TBL] [Abstract][Full Text] [Related]
4. Application of iPS cell technology to cancer epigenome study: uncovering the mechanism of cell status conversion for drug resistance in tumor.
Matsuda Y; Semi K; Yamada Y
Pathol Int; 2014 Jul; 64(7):299-308. PubMed ID: 25047500
[TBL] [Abstract][Full Text] [Related]
5. Cellular reprogramming and cancer development.
Semi K; Matsuda Y; Ohnishi K; Yamada Y
Int J Cancer; 2013 Mar; 132(6):1240-8. PubMed ID: 23180619
[TBL] [Abstract][Full Text] [Related]
6. Current status in cancer cell reprogramming and its clinical implications.
Izgi K; Canatan H; Iskender B
J Cancer Res Clin Oncol; 2017 Mar; 143(3):371-383. PubMed ID: 27620745
[TBL] [Abstract][Full Text] [Related]
7. Emerging methods for preparing iPS cells.
Miyazaki S; Yamamoto H; Miyoshi N; Takahashi H; Suzuki Y; Haraguchi N; Ishii H; Doki Y; Mori M
Jpn J Clin Oncol; 2012 Sep; 42(9):773-9. PubMed ID: 22826352
[TBL] [Abstract][Full Text] [Related]
8. Tumoral reprogramming: Plasticity takes a walk on the wild side.
Campos-Sánchez E; Cobaleda C
Biochim Biophys Acta; 2015 Apr; 1849(4):436-47. PubMed ID: 25038581
[TBL] [Abstract][Full Text] [Related]
9. Early epigenetic cancer decisions.
Martín-Lorenzo A; Gonzalez-Herrero I; Rodríguez-Hernández G; García-Ramírez I; Vicente-Dueñas C; Sánchez-García I
Biol Chem; 2014 Nov; 395(11):1315-20. PubMed ID: 25205718
[TBL] [Abstract][Full Text] [Related]
10. Reprogramming cancer cells: overview & current progress.
Lim KL; Teoh HK; Choong PF; Teh HX; Cheong SK; Kamarul T
Expert Opin Biol Ther; 2016 Jul; 16(7):941-51. PubMed ID: 27070264
[TBL] [Abstract][Full Text] [Related]
11. Prevention of tumor risk associated with the reprogramming of human pluripotent stem cells.
Wuputra K; Ku CC; Wu DC; Lin YC; Saito S; Yokoyama KK
J Exp Clin Cancer Res; 2020 Jun; 39(1):100. PubMed ID: 32493501
[TBL] [Abstract][Full Text] [Related]
12. Reprogramming of human cancer cells to pluripotency for models of cancer progression.
Kim J; Zaret KS
EMBO J; 2015 Mar; 34(6):739-47. PubMed ID: 25712212
[TBL] [Abstract][Full Text] [Related]
13. [Application of reprogramming technology for cancer research].
Yagi M; Semi K; Yamada Y
Nihon Rinsho; 2015 May; 73(5):751-5. PubMed ID: 25985626
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms underlying the formation of induced pluripotent stem cells.
González F; Huangfu D
Wiley Interdiscip Rev Dev Biol; 2016; 5(1):39-65. PubMed ID: 26383234
[TBL] [Abstract][Full Text] [Related]
15. Identification of the specific epigenetic alterations associated with chemo-resistance via reprogramming of cancer cells.
Kim JJ; Rai R
Med Hypotheses; 2015 Dec; 85(6):710-4. PubMed ID: 26527497
[TBL] [Abstract][Full Text] [Related]
16. Transcription factor-mediated reprogramming: epigenetics and therapeutic potential.
Firas J; Liu X; Lim SM; Polo JM
Immunol Cell Biol; 2015 Mar; 93(3):284-9. PubMed ID: 25643615
[TBL] [Abstract][Full Text] [Related]
17. Direct cardiac reprogramming: progress and challenges in basic biology and clinical applications.
Sadahiro T; Yamanaka S; Ieda M
Circ Res; 2015 Apr; 116(8):1378-91. PubMed ID: 25858064
[TBL] [Abstract][Full Text] [Related]
18. Xenopatients 2.0: reprogramming the epigenetic landscapes of patient-derived cancer genomes.
Menendez JA; Alarcón T; Corominas-Faja B; Cuyàs E; López-Bonet E; Martin AG; Vellon L
Cell Cycle; 2014; 13(3):358-70. PubMed ID: 24406535
[TBL] [Abstract][Full Text] [Related]
19. Common themes of dedifferentiation in somatic cell reprogramming and cancer.
Daley GQ
Cold Spring Harb Symp Quant Biol; 2008; 73():171-4. PubMed ID: 19150965
[TBL] [Abstract][Full Text] [Related]
20. Molecular barriers to processes of genetic reprogramming and cell transformation.
Chestkov IV; Khomyakova EA; Vasilieva EA; Lagarkova MA; Kiselev SL
Biochemistry (Mosc); 2014 Dec; 79(12):1297-307. PubMed ID: 25716723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
